Drug intelligence / Profile preview

MED501

Development stage: Preclinical
Lead developer: Medley Therapeutics
Modality: Gene Therapies

Overview

MED501 is an experimental genetic medicine candidate being developed by Medley Therapeutics (formerly YAP Therapeutics) for the treatment of degenerative joint disease. Currently in the discovery stage, MED501 is part of a regenerative medicine portfolio licensed from Baylor College of Medicine and the Texas Heart Institute. The therapeutic approach utilizes a genetic medicine platform designed to activate endogenous regenerative capabilities, typically by modulating the Hippo signaling pathway and its downstream effector, Yes-associated protein (YAP), to promote tissue repair and regeneration in the joints.

Beyond the preview

Go deeper on MED501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MED501.

Explore the full profile